Draft:Paul Dalby

From Wikipedia, the free encyclopedia
  • Comment: No references to significant (ie more than routine reporting or passing mentions) in reliable, independent, secondary sources with reputations for accuracy and fact-checking. Two sections completely unsupported by inline citations. Paul W (talk) 11:36, 9 May 2024 (UTC)

Paul Dalby (born 8 August 1973) is a British chemist and biochemist. He is a professor of Biochemical Engineering and Biotechnology.[1] and co-director of the Future Targeted Healthcare Manufacturing Hub[2] at University College London, where he is also Deputy Head of the Department of Biochemical Engineering.[3]

Early life and education[edit]

Dalby was born on 8 August 1973 in Northampton, UK.[citation needed] He attended Sponne School (1984–1991),[citation needed] and read Natural Sciences at Gonville and Caius College, University of Cambridge from 1991.[citation needed] Dalby was awarded a Master of Arts degree in Natural Sciences from the University of Cambridge in 1994, and carried out undergraduate research with Prof. D. H. Williams (chemistry).[citation needed] He obtained his PhD in protein folding and engineering from the University of Cambridge in 1998 under the supervision of Sir Alan Fersht at the MRC Centre for Protein Engineering.[citation needed]

Career[edit]

Dalby undertook post-doctoral research with Prof William DeGrado at the University of Pennsylvania (1998–2000), before accepting a Lectureship in Biochemical Engineering at University College London in 2000.[citation needed]

In 2013, Dalby was appointed Professor of Biochemical Engineering and Biotechnology at University College London, where he continues to work.[citation needed]

Dalby was Director of the EPSRC Centre for Doctoral Training in Innovative Manufacturing in Emergent Macromolecular Therapies (2012-2022), Co-Director of the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies (2011-2016), and Co-Director of the EPSRC Future Targeted Healthcare Manufacturing Hub (2016-2024).[2] From 2008 to 2023 Dalby was Chair of the Royal Society of Chemistry Biotechnology Group.[citation needed]

Research[edit]

Dalby applies chemical, biophysical and process engineering methods and principles to understand the properties of proteins, and then engineer or formulate them for use as therapeutics, vaccines or biocatalysts.[citation needed]

He is interested in the protein aggregation mechanisms,[4] and also how excipients stabilise therapeutic protein products[5] for applications in biotechnology.

Dalby has pioneered several strategies for combining rational, evolutionary and computational design tools, to engineer enzymes and therapeutic proteins with altered functions or improved stability.[6][7][8]

The current focuses of his group[9] are in the re-engineering and formulation of proteins, including viral vectors used in gene therapy.

Awards and honours[edit]

References[edit]

  1. ^ "Professor Paul Dalby - People in Biochemical Engineering". profiles.ucl.ac.uk/. Retrieved 2024-04-09.
  2. ^ a b "Future Targeted Healthcare Manufacturing Hub". 20 September 2018. Retrieved 2024-04-09.
  3. ^ "Biochemical Engineering". Biochemical Engineering. 13 July 2018. Retrieved 2024-04-09.
  4. ^ Codina, N.; Hilton, D.; Zhang, C.; Chakroun, N.; Ahmad, S.S.; Perkins, S.J.; Dalby, P.A. (2019). "An expanded conformation of an antibody Fab region by X-ray scattering, molecular dynamics and smFRET identifies an aggregation mechanism". Journal of Molecular Biology. 431 (7): 1409–1425. doi:10.1016/j.jmb.2019.02.009. PMID 30776431.
  5. ^ Zhang, C.; Berg, A.; Joe, C.C.D.; Dalby, P.A.; Douglas, A.D. (2023). "Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration". npj Vaccines. 8 (1): 85. doi:10.1038/S41541-023-00674-2. PMC 10240132. PMID 37277337.
  6. ^ Yu, H.; Dalby, P.A. (2018). "Exploiting correlated molecular-dynamics networks to counteract enzyme activity-stability trade-off". Proceedings of the National Academy of Sciences, USA. 115 (52): E12192–E12200. Bibcode:2018PNAS..11512192Y. doi:10.1073/pnas.1812204115. PMC 6310800. PMID 30530661.
  7. ^ Strafford, J.; et al. (2012). "Directed evolution to re-adapt a co-evolved network within an enzyme". Journal of Biotechnology. 157 (1): 237–245. doi:10.1016/j.jbiotec.2011.11.017. PMC 3657141. PMID 22154561.
  8. ^ Zhang, C.; Samad, M.; Yu, H.; Chakroun, N.; Hilton, D.; Dalby, P.A. (2018). "Computational-design to reduce conformational flexibility and aggregation rates of an antibody Fab fragment". Molecular Pharmaceutics. 15 (8): 3079–3092. doi:10.1021/acs.molpharmaceut.8b00186. PMID 29897777.
  9. ^ "Dalby profile". Dalby profile. Retrieved 2024-04-09.
  10. ^ "IChemE past awards". www.icheme.org. Retrieved 2024-04-09.
  11. ^ "Royal Society of Chemistry Rita and John Cornforth Award". rsc.org. Retrieved 2024-04-09.
  12. ^ "Candidates Nominated for Evonik European Research Award". corporate.evonik.com. Retrieved 2024-04-09.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Paul_Dalby&oldid=1223021363"